← The patent line

Inclisiran Sodium

Sold as LEQVIO · given by subcutaneous

Ten years or more until it comes off patent
10.0 yr
Until anyone may copy it
Protection runs to 2036-08-25
26
Trials running now
79 registered in total
In routine use
Furthest stage reached
already in routine clinical use
3
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Novartis Pharmaceuticals Corp
Approval holder
the only company permitted to sell it today
2036-08
Last patent expires
latest patent filed against this product
2033-02
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Atherosclerotic Cardiovascular DiseaseHypercholesterolemiaMixed Dyslipidemia
03

Who is paying for the research

Novartis Pharmaceuticals
Company
33
The Medicines Company
Company
5
Jena University Hospital
University or hospital
2

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT07684469In routine use2026 · 300 people · not yet recruiting
Comparative Assessment of Inclisiran on Top

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line